Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
Authors:
- Tia L. KauffmanTKTia L. Kauffman
- Yolanda K. PradoYPYolanda K. Prado
- Ana A. ReyesARAna A. Reyes
- Jamilyn M. ZeppJZJamilyn M. Zepp
- Jennifer SawyerJSJennifer Sawyer
- Larissa Lee WhiteLWLarissa Lee White
- Jessica MartucciJMJessica Martucci
- Suzanne Bianca SalasSSSuzanne Bianca Salas
- Sarah VertreesSVSarah Vertrees
- Alan F. RopeARAlan F. Rope
- Sheila WeinmannSWSheila Weinmann
- Nora B. HenriksonNHNora B. Henrikson
Open Access
- 13 November 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (11) , 1194
Abstract
Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs.Keywords
Funding Information
- National Cancer Institute (U01CA244323)
This publication has 41 references indexed in Scilit:
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify CarriersAnnals of Surgical Oncology, 2012
- Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance ImagingJournal of Clinical Oncology, 2011
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecologic Oncology, 2011
- Evidence-based classification of recommendations on use of genomic tests in clinical practice: Dealing with insufficient evidenceGenetics in Medicine, 2010
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA TrialJournal of Clinical Oncology, 2010
- Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography populationGenetics in Medicine, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Duty to warn at‐risk relatives for genetic disease: Genetic counselors' clinical experienceAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2002
- Transmission of human immunodeficiency virus through blood transfusion: the use of lookback and traceback approaches to optimize recipient identification in a regional populationTransfusion, 1997